ERBB2 and glioblastoma: The intracranial injection of NK-92/5.28.z CAR NK cells in patients with recurrent HER2-positive glioblastoma is being evaluated for safety and tolerability to determine the maximum tolerated dose for a phase 2 trial (NCT03383978).